Boston, MA -- (SBWIRE) -- 01/08/2014 -- Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines.

Nimenrix (Meningococcal groups A, C, Y, W-135 polysaccharide tetanus toxoid conjugate vaccine) is the brand name for GSK's tetravalent conjugate vaccine sold in the EU to protect children, adolescents, and adults against four serogroups of N. meningitidis (A, C, Y, W-135) that cause invasive meningococcal infections. Approved in the EU 2012, Nimenrix is the first tetravalent conjugate vaccine available in Europe for patients between 12 and 23 months of age.

Scope

- Overview of Meningococcal disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Nimenrix including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Nimenrix for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and Brazil.

View Full Report Details and Table of Contents

Reasons to Get This Report

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for meningococcal vaccines
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Nimenrix performance
- Obtain sales forecast for Nimenrix from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- PharmaPoint: Meningococcal Vaccines - Germany Drug Forecast and Market Analysis to 2022
- PharmaPoint: Meningococcal Vaccines - Spain Drug Forecast and Market Analysis to 2022
- PharmaPoint: Meningococcal Vaccines - Italy Drug Forecast and Market Analysis to 2022
- PharmaPoint: Meningococcal Vaccines - UK Drug Forecast and Market Analysis to 2022
- PharmaPoint: Meningococcal Vaccines - France Drug Forecast and Market Analysis to 2022
- PharmaPoint: Meningococcal Vaccines - Australia Drug Forecast and Market Analysis to 2022
- PharmaPoint: Meningococcal Vaccines - US Drug Forecast and Market Analysis to 2022
- PharmaPoint: Meningococcal Vaccines - Brazil Drug Forecast and Market Analysis to 2022
- Travel Vaccines Market to 2019 - Hepatitis A, Japanese Encephalitis and Meningococcal Vaccine Segments to Drive Growth
- Menomune (Meningococcal Vaccines) - Forecast and Market Analysis to 2022